Neurological status predicts response to alpha-blockers in men with voiding dysfunction and parkinson’s disease

Clinics

Volumn 69, Issue 12, 2014, Pages 817-822

  Gomes, Cristiano M ^a   Sammour, Zein M ^a   De Bessa Junior, Jose ^a   Barbosa, Egberto R ^a   Lopes, Roberto I ^a   Sallem, Fla´Vio S ^a   Trigo Rocha, Flavio E ^a   Bruschini, Homero ^a   Nitti, Victor W ^b   Srougi, Miguel ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Doxazosin; Lower Urinary Tract Symptoms; Parkinson s Disease; Urodynamics

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT; DOXAZOSIN;

ADULT; AGED; CLINICAL TRIAL; HUMAN; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; URODYNAMICS;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADULT; AGED; ANTIPARKINSON AGENTS; DOXAZOSIN; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PARKINSON DISEASE; PROSPECTIVE STUDIES; QUALITY OF LIFE; ROC CURVE; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; URODYNAMICS;

EID: 84921964920     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2014(12)05     Document Type: Article

References (26)

1. Samii A, Nutt JG, Ransom BR. Parkinson’s disease. Lancet. 2004;363 (9423):1783-93, http://dx.doi.org/10.1016/S0140-6736(04)16305-8.
2. Schapira AH. Disease modification in Parkinson’s disease. Lancet Neurol. 2004;3(6):362-8, http://dx.doi.org/10.1016/S1474-4422(04)00769-0.
3. Araki I, Kuno S. Assessment of voiding dysfunction in Parkinson’s disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry. 2000;68(4):429-33, http://dx.doi.org/10.1136/jnnp.68.4.429.
4. Sammour ZM, Gomes CM, Barbosa ER, Lopes RI, Sallem FS, Trigo-Rocha FE, et al. Voiding dysfunction in patients with Parkinson’s disease: impact of neurological impairment and clinical parameters. Neurourol Urodyn. 2009;28(6):510-5, http://dx.doi.org/10.1002/nau.20681.
5. Winge K, Skau AM, Stimpel H, Nielsen KK, Werdelin L. Prevalence of bladder dysfunction in Parkinsons disease. Neurourol Urodyn. 2006;25(2):116-22, http://dx.doi.org/10.1002/nau.20193.
6. Araki I, Kitahara M, Oida T, Kuno S. Voiding dysfunction and Parkinson’s disease: urodynamic abnormalities and urinary symptoms. J Urol. 2000; 164(5):1640-3.
7. Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Videourodynamic and sphincter motor unit potential analyses in Parkinson’s disease and multiple system atrophy. J Neurol Neurosurg Psychiatry. 2001;71(5):600-6, http://dx.doi.org/10.1136/jnnp.71.5.600.
8. Stohrer M, Blok B, Castro-Diaz D, Chartier-Kastler E, Del PG, Kramer G, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol. 2009;56(1):81-8, http://dx.doi.org/10.1016/j.eururo.2009.04.028.
9. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. EAU Guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. EurUrol. 2013;64(1):118-40, http://dx.doi.org/10.1016/j.eururo.2013.03.004.
10. Sakakibara R, Shinotoh H, Uchiyama T, Sakuma M, Kashiwado M, Yoshiyama M, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease. Auton Neurosci. 2001;92(12):76-85, http://dx.doi.org/10.1016/S1566-0702(01)00295-8.
11. Donovan JL, Peters TJ, Abrams P, Brookes ST, aa Rosette JJ, Schafer W. Scoring the short form ICSmaleSF questionnaire. International Continence Society. J Urol. 2000;164(6):1948-55.
12. Schafer W. Principles and clinical application of advanced urodynamic analysis of voiding function. Urol Clin North Am. 1990;17(3):553-66.
13. Pavlakis AJ, Siroky MB, Goldstein I, Krane RJ. Neurourologic findings in Parkinson’s disease. J Urol 1983;129(1):80-3.
14. Christmas TJ, Kempster PA, Chapple CR, Frankel JP, Lees AJ, Stern GM, et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet. 1988;2(86268627):1451-3, http://dx.doi.org/10.1016/ S0140-6736(88)90932-4.
15. Fowler CJ. Urinary disorders in Parkinson’s disease and multiple system atrophy. Funct Neurol. 2001;16(3):277-82.
16. Galloway NT. Urethral sphincter abnormalities in Parkinsonism. Br J Urol. 1983;55(6):691-3
17. Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2003;170(2 Pt 1):498-502.
18. Rossi C, Kortmann BB, Sonke GS, Floratos DL, Kiemeney LA, Wijkstra H, et al. alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it. J Urol. 2001;165(1):38-41.
19. Staskin DS, Vardi Y, Siroky MB. Post-prostatectomy continence in the parkinsonian patient: the significance of poor voluntary sphincter control. J Urol. 1988;140(1):117-8.
20. Roth B, Studer UE, Fowler CJ, Kessler TM. Benign prostatic obstruction and parkinson’s disease–should transurethral resection of the prostate be avoided? J Urol. 2009;181(5):2209-13.
21. Seki S, Igawa Y, Kaidoh K, Ishizuka O, Nishizawa O, Andersson KE. Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats. Neurourol Urodyn. 2001;20(1):105-13, http://dx.doi.org/ 10.1002/1520-6777(2001)20:1,105::AID-NAU12.3.0.CO;2-9.
22. Kortmann BB, Floratos DL, Kiemeney LA, Wijkstra H, de la Rosette JJ. Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials. Urology. 2003;62(1):1-9, http://dx.doi.org/10.1016/S0090-4295(02) 02113-1.
23. Yoshiyama M, de Groat WC. Role of spinal alpha1-adrenoceptor subtypes in the bladder reflex in anesthetized rats. Am J Physiol Regul Integr Comp Physiol. 2001;280(5):R1414-9.
24. Hampel C, Dolber PC, Smith MP, Savic SL, Th rJ, Thor KB, et al. Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol. 2002;167(3):1513-21.
25. Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. Campbell’s Urology. 8 ed. Philadelphia: W. B. Saunders Co.; 2002. p. 1297-330.
26. Winge K, Werdelin L., Nielsen KK, Stimpel H. Effects of dopaminergic treatment on bladder function in Parkinson’s disease. Neurourol Urodyn. 2004;23(7):689-96, http://dx.doi.org/10.1002/nau.20054